Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Abdelhak A, Hottenrott T, Morenas-Rodríguez E, Suárez-Calvet M, Zettl UK, Haass C, Meuth SG, Rauer S, Otto M, Tumani H, Huss A.

Front Neurol. 2019 Mar 26;10:280. doi: 10.3389/fneur.2019.00280. eCollection 2019.

2.

Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases.

Boxberger N, Hecker M, Zettl UK.

J Immunol. 2019 Apr 15;202(8):2177-2187. doi: 10.4049/jimmunol.1801416. Review.

PMID:
30962309
3.

Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.

Frahm N, Hecker M, Zettl UK.

Sci Rep. 2019 Mar 6;9(1):3743. doi: 10.1038/s41598-019-40283-5.

4.

A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene.

Hecker M, Boxberger N, Illner N, Fitzner B, Schröder I, Winkelmann A, Dudesek A, Meister S, Koczan D, Lorenz P, Thiesen HJ, Zettl UK.

PLoS Genet. 2019 Feb 7;15(2):e1007961. doi: 10.1371/journal.pgen.1007961. eCollection 2019 Feb.

5.

Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study.

Frahm N, Hecker M, Zettl UK.

PLoS One. 2019 Jan 24;14(1):e0211120. doi: 10.1371/journal.pone.0211120. eCollection 2019.

6.

TPP2 mutation associated with sterile brain inflammation mimicking MS.

Reinthaler EM, Graf E, Zrzavy T, Wieland T, Hotzy C, Kopecky C, Pferschy S, Schmied C, Leutmezer F, Keilani M, Lill CM, Hoffjan S, Epplen JT, Zettl UK, Hecker M, Deutschländer A, Meuth SG, Ahram M, Mustafa B, El-Khateeb M, Vilariño-Güell C, Sadovnick AD, Zimprich F, Tomkinson B, Strom T, Kristoferitsch W, Lassmann H, Zimprich A.

Neurol Genet. 2018 Nov 13;4(6):e285. doi: 10.1212/NXG.0000000000000285. eCollection 2018 Dec.

7.

Headache in the course of multiple sclerosis: a prospective study.

Gebhardt M, Kropp P, Hoffmann F, Zettl UK.

J Neural Transm (Vienna). 2019 Feb;126(2):131-139. doi: 10.1007/s00702-018-1959-0. Epub 2018 Nov 30.

PMID:
30506270
8.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

9.

Headache at the Time of First Symptom Manifestation of Multiple Sclerosis: A Prospective, Longitudinal Study.

Gebhardt M, Kropp P, Hoffmann F, Zettl UK.

Eur Neurol. 2018;80(3-4):115-120. doi: 10.1159/000494092. Epub 2018 Oct 26.

PMID:
30368493
10.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

11.

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.

Rommer PS, Eichstädt K, Ellenberger D, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK.

Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580. [Epub ahead of print]

PMID:
30230952
12.

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.

Ellenberger D, Eichstädt K, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK, Rommer PS.

Mult Scler Relat Disord. 2018 Oct;25:173-174. doi: 10.1016/j.msard.2018.07.040. Epub 2018 Jul 24. No abstract available.

PMID:
30096682
13.

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, Zettl UK.

CNS Neurosci Ther. 2019 Feb;25(2):245-254. doi: 10.1111/cns.13034. Epub 2018 Jul 25.

PMID:
30044050
14.

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.

Koczan D, Fitzner B, Zettl UK, Hecker M.

Sci Data. 2018 Jul 24;5:180145. doi: 10.1038/sdata.2018.145.

15.

Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.

Winkelmann A, Rommer PS, Hecker M, Zettl UK.

CNS Neurosci Ther. 2019 Jan;25(1):78-85. doi: 10.1111/cns.12985. Epub 2018 Jun 1.

PMID:
29858532
16.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.

Rommer PS, Zettl UK.

Lancet Neurol. 2018 Jun;17(6):497-498. doi: 10.1016/S1474-4422(18)30161-3. No abstract available.

PMID:
29778357
17.

The sphingosine analog fingolimod (FTY720) enhances tone and contractility of rat gastric fundus smooth muscle.

Kraft M, Zettl UK, Noack T, Patejdl R.

Neurogastroenterol Motil. 2018 Oct;30(10):e13372. doi: 10.1111/nmo.13372. Epub 2018 May 8.

PMID:
29740911
18.

Coping behavior in multiple sclerosis-complementary and alternative medicine: A cross-sectional study.

Rommer PS, König N, Sühnel A, Zettl UK.

CNS Neurosci Ther. 2018 Sep;24(9):784-789. doi: 10.1111/cns.12857. Epub 2018 Apr 10.

19.

Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.

Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbäumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE).

Ann Neurol. 2018 Apr;83(4):863-869. doi: 10.1002/ana.25216.

PMID:
29572931
20.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
21.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
22.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

23.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
24.

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Löbermann M, Handorn B, Winkelmann A, Reisinger EC, Hartung HP, Zettl UK.

Nervenarzt. 2018 Oct;89(10):1172-1178. doi: 10.1007/s00115-018-0492-6. Review. German.

PMID:
29404651
25.

Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge.

Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS.

Expert Rev Clin Immunol. 2018 Feb;14(2):137-153. doi: 10.1080/1744666X.2018.1426462. Epub 2018 Jan 23.

PMID:
29318902
26.

Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.

Angerer IC, Hecker M, Koczan D, Roch L, Friess J, Rüge A, Fitzner B, Boxberger N, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Meister S, Zettl UK.

CNS Neurosci Ther. 2018 Mar;24(3):193-201. doi: 10.1111/cns.12793. Epub 2018 Jan 3.

PMID:
29314605
27.

Headache in the first manifestation of Multiple Sclerosis - Prospective, multicenter study.

Gebhardt M, Kropp P, Jürgens TP, Hoffmann F, Zettl UK.

Brain Behav. 2017 Nov 16;7(12):e00852. doi: 10.1002/brb3.852. eCollection 2017 Dec.

28.

Information processing deficits as a driving force for memory impairment in MS: A cross--sectional study of memory functions and MRI in early and late stage MS.

Köhler W, Fischer M, Bublak P, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Stadler E, Zettl UK, Penner IK; HIPPOCOMS Study Group.

Mult Scler Relat Disord. 2017 Nov;18:119-127. doi: 10.1016/j.msard.2017.09.026. Epub 2017 Sep 25.

PMID:
29141793
29.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2018 Oct;24(11):1507-1510. doi: 10.1177/1352458517739137. Epub 2017 Nov 9.

30.

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.

Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK.

Int J Mol Sci. 2017 Aug 11;18(8). pii: E1749. doi: 10.3390/ijms18081749.

31.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

32.

Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions.

Patejdl R, Zettl UK.

Autoimmun Rev. 2017 Sep;16(9):925-936. doi: 10.1016/j.autrev.2017.07.004. Epub 2017 Jul 8. Review.

PMID:
28698092
33.

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.

Friess J, Hecker M, Roch L, Koczan D, Fitzner B, Angerer IC, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Zettl UK.

Sci Rep. 2017 Feb 3;7:42087. doi: 10.1038/srep42087.

34.

The Development of Sayk's Cell Sedimentation Chamber: A Historical View on Clinical Cerebrospinal Fluid Diagnostics.

Dahlmann N, Zettl UK, Kumbier E.

Eur Neurol. 2017;77(3-4):162-167. doi: 10.1159/000456003. Epub 2017 Jan 25.

35.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

36.

[Diagnostic Workup and Treatment of Antibody-Related Encephalomyelitis].

Patejdl R, Winkelmann A, Ehler J, Zettl H, Meister S, Zettl UK.

Fortschr Neurol Psychiatr. 2016 Oct;84(S 02):S88-S91. Epub 2016 Nov 2. Review. German.

PMID:
27806422
37.

[Autoimmune-Mediated Encephalomyelitis: a Heterogeneous Entity in Between Neurology and Psychiatry].

Zettl UK, Dudesek A, Rimmele F, Zettl H, Patejdl R.

Fortschr Neurol Psychiatr. 2016 Oct;84(S 02):S84-S87. Epub 2016 Nov 2. Review. German.

PMID:
27806421
38.

Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.

Zettl UK, Schreiber H, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; BETAPATH Study Group.

Acta Neurol Scand. 2017 Aug;136(2):116-121. doi: 10.1111/ane.12705. Epub 2016 Oct 30.

PMID:
27796033
39.

Hans Queckenstedt (1876-1918).

Kumbier E, Zettl UK.

J Neurol. 2017 May;264(5):1032-1034. doi: 10.1007/s00415-016-8315-9. Epub 2016 Oct 19. No abstract available.

PMID:
27761642
40.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

41.

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms.

Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L.

Sci Rep. 2016 Oct 3;6:34512. doi: 10.1038/srep34512.

42.

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; Study Group.

BMC Neurol. 2016 Sep 21;16(1):181.

43.

Neuromyelitis optica spectrum disorder coinciding with hematological immune disease: A case report.

Patejdl R, Wittstock M, Zettl UK, Jost K, Grossmann A, Prudlo J.

Mult Scler Relat Disord. 2016 Sep;9:101-3. doi: 10.1016/j.msard.2016.07.006. Epub 2016 Jul 8.

PMID:
27645353
44.

High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.

Roch L, Hecker M, Friess J, Angerer IC, Koczan D, Fitzner B, Schröder I, Flechtner K, Thiesen HJ, Meister S, Winkelmann A, Zettl UK.

Mol Neurobiol. 2017 Sep;54(7):5511-5525. doi: 10.1007/s12035-016-0075-0. Epub 2016 Sep 8.

PMID:
27631876
45.

Coping with multiple sclerosis-the role of social support.

Rommer PS, Sühnel A, König N, Zettl UK.

Acta Neurol Scand. 2017 Jul;136(1):11-16. doi: 10.1111/ane.12673. Epub 2016 Sep 12.

PMID:
27620927
46.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

47.

Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.

Skierlo S, Rommer PS, Zettl UK.

Acta Neurol Scand. 2017 Apr;135(4):394-399. doi: 10.1111/ane.12612. Epub 2016 Jun 9.

PMID:
27283842
48.

Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.

Papathemeli D, Gräfe R, Hildebrandt U, Zettl UK, Ulrich J.

Mult Scler. 2016 Dec;22(14):1888-1890. Epub 2016 Apr 26.

PMID:
27207455
49.

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.

G3 (Bethesda). 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841.

50.

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.

Zettl UK, Bauer-Steinhusen U, Glaser T, Czekalla J, Hechenbichler K, Limmroth V, Hecker M.

Adv Ther. 2016 May;33(5):834-47. doi: 10.1007/s12325-016-0325-6. Epub 2016 Apr 18.

PMID:
27090116

Supplemental Content

Loading ...
Support Center